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Hypoxia activates hypoxia-inducible factor 1, which promotes the progression of
malignancy by stimulating angiogenesis and by augmenting the ability of tumors
to survive. Thus, HIF-1 is one of the most compelling targets for treating
cancers. The aim of this study was to find a small molecule that inhibits HIF-1
under hypoxia in cancer cells. 7,280 compounds in a chemical library were tested
in a cancer cell line expressing luciferase HIF-dependently. Through three
rounds of screening, I finally picked up a compound that originates from a
marine bacterium parasitizing red alga. The antibiotic potently inhibited HIF-1
expression and its transcriptional activity in cancer cells exposed to hypoxia.
Through two-step fractionation, diacetoxyscirpenol was purified and identified as
a HIF-inhibiting ingredient. Mechanistically, diacetoxyscirpenol inhibits the
synthesis of HIF-1α protein and also interferes with the dimerization of HIF-1α 
and ARNT. It attenuates HIF-mediated gene expression in cancer cells exposed
to hypoxia, and by doing so reduces tumorigenic and angiogenic potentials of
cancer cells. More importantly, diacetoxyscirpenol retarded tumor growth in
mice, and reduced HIF-1α expression and vascular formation in the tumors.
Overall, diacetoxyscirpenol is considered a potential drug deregulating the HIF-1
ii
signaling pathway, and it could be beneficially employed for treating malignant
tumors with hypoxic microenvironment.
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INTRODUCTION
Hypoxia is a common feature in solid tumors and plays crucial roles for tumor
progression and angiogenesis [Harris et al., 2002; Pugh et al., 2003]. To survive
under a hypoxic microenvironment, cancer cells require the activation of many
genes essential for their adaptation to the condition, which is mainly driven by
the transcription factor HIF-1 (hypoxia-inducible factor 1) [Wang et al., 1995].
The HIF family are composed of α and β subunits [Pugh et al., 1997; Bardos et
al., 2005]. There are well known isoform of HIF-α : HIF-1α, HIF-2α 
(alternatively named endothelial PAS domain protein-1, EPAS-1). HIF-1β also
known as aryl hydrocarbon receptor nuclear translocator (ARNT) is a common
binding partner for HIF-1α and HIF-2α [Rocha et al., 2007]. The HIF subunits
share basic helix-loop-helix (bHLH) and Per/ARNT/Sim (PAS) domains
[Semenza et al., 1985]. In addition, they possess an oxygen-dependent
degradation domain (ODDD), which renders HIF-α protein labile in the presence
of oxygen. HIF-1α and HIF-2α contain two transactivation domains (TADs),
namely, the N-terminal TAD (NAD) and the C-terminal TAD (CAD).
HIF-1α is rapidly degraded under normoxic conditions, when it is hydroxylated
at two proline residues (Pro 402 and Pro 564) within the ODDD by hydroxylase
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domain (PHD) 1-3 [Fandrey et al., 2006]. This post-translational modification
serves as a recognition motif for subsequent ubiquitination by the E3 ubiquitin
ligase activity of the von Hippel-Lindau tumor (pVHL) suppressor protein, thus
targeting HIF-1α for degradation by the 26S proteasome [Ivan et al., 2001;
Jaakkola et al., 2001; Maxwell et al., 1999]. In hypoxic conditions, hydroxylation
of HIF-1a does not occur, and the a subunit is free to migrate to the nucleus,
bind to its counterpart, and thus act as a transcription factor along with other
cofactors. An additional level of regulation mediated by cellular oxygen levels is
given by the factor inhibiting HIF (FIH-1) [Dayan et al., 2006], an asparagine
hydroxylase that hydroxylates the N803 residue in the carboxyl-terminal
transactivation domain (CAD) of HIF-1α. In hypoxic conditions, N803 is not
hydroxylated by FIH-1; therefore, HIF-1α can interact with its transcriptional
coactivators, p300 and CBP (CREB binding protein), and hence further promote
transcription of genes that have hypoxia responsive enhancer elements in their
promoter region [Mahon et al., 2001; Lando et al., 2002].
The expression of HIF-1 in tumor specimens positively correlates with tumor
aggressiveness and poor prognosis [Birner et al., 2000]. Also, many tumor
grafting studies have supported the positive effects of HIF-1 on tumorigenesis,
tumor growth, and tumor invasion [Ryan et al., 2000]. Given clinical and
experimental evidence, HIF-1 has been believed as a promising target for
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treating tumors. Indeed, many types of HIF-1 inhibitors have been discovered,
and some of them are currently under clinical trials. HIF-1 inhibitors act through
various mode-of-actions as followings (Table 1).
Bortezomib, nutlin-3, and echinomycin functionally inhibit the HIF-1-mediated
gene expressions [Shin et al., 2008; Lee et al., 2009; Kong et al., 2005]. HSP90
inhibitors, microtubule disruptors, and YC-1 destabilize HIF-1α in the
post-translational level [Isaacs et al., 2002 Ricker et al., 2004; Yeo et al., 2003].
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Several agents, such as topotecan, camtothecin, digoxin, rapamycin, LY294002
and chaetocin, have been reported to block de novo synthesis of HIF-1α protein
[Raspisarda et al., 2004; Lou et al., 2010; Zhang et al., 2008; Hudson et al., 2002;
Zhong et al., 2000; Lee et al., 2011].
In spite of many efforts to discover small-molecule inhibitors of the HIF
signaling pathway, none of the inhibitors has been identified to directly
(physically) target the HIF-α proteins. Actually, all of them indirectly control the
HIF signaling pathway by inhibiting the non-selective regulators that also
participate in the de novo synthesis or stabilization of proteins other than HIF-
α. Nonetheless, some of those inhibitors, such as camptothecin, topotecan,
bortezomib, echinomycin, 17-AAG, were FDA-approved for cancer treatment.
Yet, they have not been clinically used so far because they could make adverse
effects due to lack of specificity. To realize the HIF-targeting cancer therapy,
the molecules targeting HIF-α per se should be discovered, so it is still worth
while to search for new HIF inhibitors.
The aim of this study was to find a small molecule that inhibits HIF-1 specific
under hypoxia in cancer cells. A human hepatoma cell line, which stably
expresses the luciferase reporter gene targeted by HIF-1, was established and
used for searching for HIF-1 inhibitors in a chemical library containing 7,280
compounds. Finally, I picked up a compound that originates from a marine
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bacterium living on red alga, and identified this compound as diacetoxyscirpenol.
Moreover, I examined how the compound inhibits HIF-1 and whether it has
anti-cancer and anti-angiogenic activities.
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MATERIALS AND METHODS
1. Cell culture and transfection
Hep3B (hepatoma), A549 (lung cancer), HCT116 (colon cancer) and LLC1
(mouse lung cancer) cell lines were obtained from the American Type Culture
Collection (Manassas, VA). MKN45 (gastric cancer) was obtained from Korean
Cell Line Bank (Seoul, Korea). RCC4 / VHL-/- (renal cancer) was obtained from
European Collection of Authenticated Cell Cultures (London, UK). The cells were
cultured in Minimum Essential Media, Dulbecco’s Modified Eagle Medium or
RPMI-1640, supplemented with 10 % heat-inactivated FBS. Cells were incubated
in a humidified atmosphere at 37 ᵒC under 20 % O2 / 5 % CO2 for normoxia or
1 % O2 / 5 % CO2 hypoxia. For transient transfection, cells at about 40 %
confluence were transfected with plasmids using Lipofectamin 2000 (Life
Technologies, Carlsbad, CA). Cells were allowed to stabilize for 48 hours before
being used in experiments.
2. Reagents and antibodies
Diacetoxyscirpenol was purchased from LKT laboratories (Saint Paul, MN), and
17AAG and DMOG from Sigma-Aldrich Corp (St Louis, MO). Anti-HIF-2α 
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(#7096) antibody was purchased from Cell Signaling Technology (Danvers, MA),
and antibodies against ARNT (sc-8076), β-tubulin (sc-9104) and lamin-B
(sc-6216) from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-HIF-1α 
antiserum was generated in rabbits against a bacterially expressed fragment
encompassing amino acids 418 to 698 of human HIF-1α.
3. Chemical library and fractionation of marine bacterial metabolites
A chemical library containing 7,280 compounds was kindly provided by Korea
Chemical Bank (Daejeon, Korea; http://www.chembank.org/). A bacterial strain
Bacillus licheniformis was isolated from the marine red alga Gelidium pacificum
collected at Geomun Island in South Korea, and identified based on 18S rRNA
analyses (performed in SolGent Co., Ltd., Daejeon, Korea). The bacterium was
cultured in 20 L of culture medium consisting of soytone (0.1 %), soluble starch
(1.0 %), and seawater (100 %). The cultures were incubated at 29 °C for 20 days
on the static condition. The whole culture was filtered through cheesecloth to
yield broth and mycelium residue, and the resulted broth were extracted with
EtOAc to afford broth extract (1.1 g). The broth extract was subjected to silica
gel flash column chromatography. Elution was performed with n-hexane-EtOAc
(stepwise, 0–100% EtOAc) to yield eight fractions. Fraction 5 (15.5 mg)
displayed HIF activity, and was further purified by silica gel flash column
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chromatography using n-hexane-EtOAc (stepwise, 10–100% EtOAc) to give
crude diacetoxyscirpenol (8.0 mg), which was finally purified by LH-20 column
chromatography (MeOH) to furnish diacetoxyscirpenol (1.5 mg).
4. Reporter assays
To construct the EPO enhancer-driven luciferase reporter gene, the human
EPO enhancer region (5-GGTACCGGCCCTACGTGCTGTCTCACACAGCCT
GTCTGACCTCTCGACCTACCGGCCAGATCT-3) was inserted into the
multi-cloning site of the pGL4 vector (Promega, Madison, WI). Mutated EPO
luciferase was generated by altering the DNA sequence targeted by HIF-1
(CGTG to AAAA). Hep3B cells were transfected with 1 mg of the reporter
plasmid using Lipofectamin 2000 (Life Technologies). After stabilized for 48
hours, the Hep3B cell lines stably harboring the reporter plasmid were selected
under G418, and five stable cell lines were mixed to rule out the artifact
generated by the integration of the plasmid into chromosomes. The cell line was
pre-treated with each compound in a chemical library for 4 hours, and then
incubated under normoxia or hypoxia for 16 hours. Cells were lysed and
luciferase activity was measured using a LB960 luminometer (Berthold
Technologies, Oak Ridge, TN). To evaluate the capdependent and the
IRES-dependent translation of HIF-1α mRNA, I used thymidine kinase (TK)
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promoter / HIF-1α 5‘-UTR / luciferase and CMV promoter / GFP / HIF-1α 
5‘-UTR/luciferase reporters, respectively [Cho et al., 2009]. The β-gal expression
plasmid was co-transfected into cells to normalize transfection efficiency.
5. Cell viability assays
An MTT labeling reagent (Sigma-Aldrich, St Louis, MI) was used to evaluate
cytotoxicity. Cells were plated in 24-well dishes and cultured in 0.5 ml of
medium per well. After cells were treated with each compound for 24 hours,
cells were incubated with 5 mg/mL of MTT for 3 hours. Blue formazan crystals
were solubilized with acidified isopropanol, and formazan levels were determined
at 570 nm using a spectrophotometer.
6. Immunoblotting and immunoprecipitation
Total proteins were separated on an SDS polyacrylamide gel and transferred to
Immobilon-P membranes (Millipore, Bedford, MA). Membranes were blocked
with 5 % nonfat milk in a 0.1 % Tween-20 / Trisbuffered saline (TTBS) at room
temperature for 1 hour, and sequentially incubated overnight at 4 ᵒC with a
primary antibody (1:1000) and with horseradish peroxidaseconjugated secondary
antibody (1:5000) for 1 hour. The immune complexes were visualized using an
Enhanced Chemiluminescence Plus kit (Amersham Biosciences, Piscataway, NJ).
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The intensities of HIF-1/2α blots were quantified using Image J program v1.31
(NIH, Bethesda, MD) and normalized to β-tubulin levels. Data from 3
independent experiments were compared statistically. To analyze the interaction
between HIF-1α and ARNT, cell lysates were incubated with anti-HIF-1α 
antibody for 4 hours, and further incubated with protein A/G-Sepharose beads
(GE Healthcare BioSciences, Westborough, MA) at 4 ᵒC for 2 hours.
Co-precipitated ARNT was identified by immunoblotting with anti-ARNT
antibody.
7. Immunofluorescence
A549 cells were cultured on glass coverslips. The cells were fixed with 4 %
paraformaldehyde for 30 minutes, washed twice with PBS, blocked with 5 %
FBS, and incubated with anti-HIF-1α antibody for 16 hours. The cells were
incubated with anti-rabbit IgG antibody conjugated with Alexa Fluor® 488 for 1
hour, and their nuclei were stained with 30 μM DAPI for 5 minutes. Finally, the
cells were mounted with the Fluorescence Mounting Medium (Thermo Fisher
Scientific, Waltham, MA) and photographed under a fluorescence microscope.
8. Secreted VEGF assay
A549 cell was treated with a compound under normoxia and hypoxia for 24
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hours. VEGF released from cells was analyzed in medium using the human
VEGF ELISA kit provided by Life Technologies. The VEGF levels were
calculated based on the standard curve using a recombinant human VEGF 165.
Each assay was triplicate to reduce the intra-assay error.
9. Quantitative RT-PCR
Total RNAs were reverse-transcribed, and realtime polymerase chain reaction
analyses were performed in 96-well optical plates. Data were analyzed using
CFX Manager Software (Bio-Rad Laboratories, Hercules, CA), and values were
normalized to β-actin. The sequences (5’ to 3’) of primers are
ACCAAGGGACATCAGATTTC & GTAGCCATAGTCACAGGATG for lysyl
ox idase (LOX) ; GGAAGAAAACAGTGCCTATG & GTGTAGTCAGAG
ACCCCTCA for carbonic anhydrase IX (CA9); ACCCACCTCCCTTATGTAGT &
CCAACTAATGCAATTT TTCC for CBP/p300-interacting transactivator with
G/D-rich carboxy-terminal domain 2 (CITED2); GGAGGAGAACAAACAGATCA
& GTAGGACAGGAAGTTGTTGG for cyclin D1; GTTGCCACTTCCACATAATG
&TCATCTGTGCTTTCATGTCA for HIF-1α; GTGGACATCTTCCAGGAGTA
& GTGATGTTGGACTCCTCAGT for vascular endothelial growth factor
(VEGF); and GGACCTGACTGACTACCTCA & AGCTTCTCCTTAATGTCACG
for β-actin.
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10. Anchorage-independent tumor growth assay
The top agar mixture (RPMI-1640 with 10 % fetal bovine serum, 0.4 % agar,
and 2 × 103 A549 cells) was poured into a dish which had been coated with 0.8
% agar, and solidified. Cells were incubated for 3weeks, and fresh media
containing compounds were administered twice a week. Colonies were identified
and calculated under an inverted microscope at × 100 magnification.
11. Endothelial tube formation assay
Endothelial tube formation assay was conducted on the Matrigel (BD
Biosciences, San Jose, CA), which was added to a 24-well plate in a volume of
100 μL/well and allowed to be polymerized at 37ᵒC for 30 minutes. Human
umbilical vein endothelial cells (HUVECs) at a density of 2 × 104 were seeded
into each well and incubated with 0.5 mL of MEDIUM 199 (Sigma-Aldrich)
containing 1 % FBS. After stabilized, cells were incubated in the conditioned
media driven by A549 cells for 16 hours. Images were captured with OLYMPUS
camera attached to the microscope. The tube formation was quantified by
measuring the long axis of the individual cells using Image J.
12. Animals and tumor grafts
Male nude mice (BALB/cAnNCrj-nu/nu) were purchased from Charles River
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Japan (Shin-Yokohama, Japan) and housed in a specific pathogen-free room.
Mice (11 weeks old) were injected subcutaneously in a flask with 1 × 106 LLC1
cells. After tumor volumes reached over 100 mm3, mice were intraperitoneally
injected with dimethyl sulfoxide (DMSO) or DAS (1 mg/kg) once a day. Tumor
volumes were measured with a caliper and calculated using the equation “a ×
b2/2”, where ‘a’ is the maximal width and ‘b’ is maximal orthogonal width. All
animal procedures were performed in accordance with a protocol approved by
the Institutional Animal Care and Use Committee (Approve # SNU-141008-1).
13. Immunohistochemistry
Xenograft tumor tissue specimens were deparaffinized, autoclaved to retrieve
antigens, and sequentially incubated with 3 % H2O2, a primary antibody
(anti-HIF-1α, anti-CD31, Thermo Fisher, Rockfordd, IL; anti-Ki67, Leica
Biosystems, Richmond, IL), and a biotinylated secondary antibody (Vector
Laboratories, Burlingame, CA). The immune complexes were visualized using
Vectastatin ABC (Vector Laboratories), and the specimens were counterstained
with hematoxylin. Histology and immunostaining were reviewed under a




Statistical analyses were performed using the Microsoft Excel (2010) software
and values were described as means and standard deviation. The differences
between two groups were analyzed by two-sided, unpaired Student t-test, and
were considered statistically significant when P < 0.05.
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RESULTS
Screening of HIF-1 inhibitors
I established the stable Hep3B cell line that expresses luciferase HIF-1
dependently under hypoxia (Fig. 1A) and searched for anti-HIF-1 compounds, as
was summarized in Fig. 1B. I first checked chemiluminescence emitting form the
cells which had been incubated at 1% oxygen with DMSO or each (finally 5 μ
g/mL) of 7,280 compounds in a chemical library for 16 hours. From the
first-round screening, I picked up 166 candidates. To rule out the possibility that
luciferase expression is nonspecifically impaired due to toxicity, I checked
whether the candidates at 5 mg/mL were not toxic (less than 20 % cell death)
using MTT analysis. From the second-round screening, 27 compound were
selected as HIF-1 inhibitors. To further search for potent inhibitors, I
reevaluated the anti-HIF-1 effects of 27 candidates at a concentration of 1
mg/mL and picked up three candidates. Finally, I selected the most potent
compound “BHS-A503” that inhibited HIF-1 at < 100 ng/mL. The compound was
an unrefined extract from Bacillus licheniformis, which is parasitic on red alga
Gelidium pacificum.
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Purification and identification of a HIF-1inhibitor from the BHS-A503
fraction
To purify a single compound from the bacterial extract, I performed silica-gel
flash chromatography and separated the extract into 40 fractions. Of them, I
picked up the fraction 26 because it inhibited HIF-1 activity by > 85% (Fig. 1C)
and was also not significantly toxic (Fig. 1D). The effects of the fractions
against HIF-1 were rechecked by evaluating the HIF-1α protein level using
Western blotting. As was expected, HIF-1α protein was not detected under
normoxia but was notably induced under hypoxia. I also found that the fraction
26 at 100 ng/mL attenuated the hypoxic induction of HIF-1α almost completely
(Fig. 1E). Since the fraction 26 was not a single compound, I further separated
the fraction 26 into 13 fractions using LH-20 column chromatography.
Consequently, the 7th fraction of the fraction 26, which is designated #26-7, was
identified not only to inhibit HIF-1 activity even at 10 ng/mL but also to be
less toxic (Fig. 2A and 2B). A Western blotting showed that #26-7 suppressed
HIF-1α expression very effectively (Fig. 2C).
Anti-HIF effects of #26-7 in different cancer cell lines
We next examined whether #26-7 has anti-HIF activity in cancer cells other
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than Hep3B. #26-7 suppressed HIF-1α expression in a dose-dependent manner,
whereas it did not substantially affect ARNT expression (Fig. 3A) Likewise,
#26-7 also effectively suppressed HIF-1α expression in HCT116 and MKN45
cells (Fig. 3B). Apparently, the efficacy of #26-7 on HIF-1α inhibition appears to
be similar among three cell lines.
In the EPO enhancer reporter assay, #26-7 was found to inhibit the HIF-1
driven transcription under hypoxia (Fig. 3C). To examine whether #26-7
regulates the cellular response to hypoxia, I analyzed mRNAs of the HIF target
genes in A549 cells. The hypoxic induction of LOX, CA9, CyclinD1, and CITED2
mRNAs was substantially attenuated by #26-7 (Fig. 3D). Using [α]D,
LR-EI-MS, and NMR (1H, 13C, DEPT) analyses, #26-7 was identify as
diacetoxyscirpenol [Cole et al., 1981]. Its structure is illustrated in Fig. 4A. First,
I compared the toxicity of the purchased diacetoxyscirpenol in A549 and two
normal cell-lines. Even at the higher concentrations of diacetoxyscirpenol, no
significant differences in toxicity were observed among the cell-lines (Fig. 4B).
Given that this reagent also inhibited the expression and activity of HIF-1/2α 
(Fig. 4C and 4D), diacetoxyscirpenol was considered an HIF-inhibiting ingredient
included in #26-7. Compared with a known HIF-1 inhibitor 17AAG,
diacetoxyscirpenol was shown to be more potent in HIF-1 inhibition (Fig. 4E).
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Diacetoxyscirpenol deregulates HIF-1 signaling in two different steps
To understand how diacetoxyscirpenol downregulates HIF-1α, I first checked the
stability of HIF-1α protein. HIF-1α degradation was induced by reoxygenation
after the protein was accumulated under hypoxia (Fig. 5A) or by cycloheximide
treatment after it was stabilized using a HIF prolyl hydroxylase inhibitor,
dimethyloxaloylglycine (DMOG) (Fig. 5B). However, the rate of HIF-1α 
degradation was not facilitated in the presence of diacetoxyscirpenol, suggesting
no effect of diacetoxyscirpenol on HIF-1α stability. Next, I analyzed de novo
synthesis of HIF-1α using MG132, which can induce the accumulation of newly
synthesized HIF-1α protein by blocking protein degradation. Strikingly, the
synthesis of HIF-1α protein was abolished by diacetoxyscirpenol (Fig. 5C). To
further examine the mechanism underlying the blockade of HIF-1α synthesis, I
measured the mRNA levels of HIF-1α, but diacetoxyscirpenol did not inhibit the
transcription of HIF-1α (Fig. 5D), which encouraged us to analyze the
translation of HIF-1α. The translation of HIF-1α mRNA is initiated through two
pathways, 5’ cap-dependent translation and internal ribosome entry site
(IRES)-dependent translation, both of which are determined by the 5’-UTR of
HIF-1α mRNA [Lang et al., 2002]. I analyzed the activities of two luciferase
reporters reflecting each pathway of HIF-1α translation. Consequently,
diacetoxyscirpenol inhibited both the pathways of HIF-1α translation, whereas it
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did not affect the activity of TK promoter without the 5’-UTR (Fig. 5E).
Diacetoxyscirpenol seems to inhibit de novo synthesis of HIF-1α protein by
blocking the 5’-UTR-mediated translation of HIF-1α mRNA. To rule out other
actions of diacetoxyscirpenol on oxygen-dependent HIF-1 regulation, I examined
if it affects the HIF-1α hydroxylation by PHD enzymes or the HIF-1α 
ubiquitination/degradation by the pVHL-E3 complex. However, diacetoxyscirpenol
suppressed HIF-1α expression even in the presence of DMOG and also in
VHL-null RCC4 cells (Fig. 6A and 6B). These findings further support our
notion that diacetoxyscirpenol does not affect the degradation process of HIF-1α.
To get its functionality as a transcription factor, HIF-1α should dimerize with
ARNT in the nucleus. Interestingly, diacetoxyscirpenol interfered with the
dimerization of HIF-1α and ARNT (Fig. 6C), which may be attributed to
impaired nuclear translocation of HIF-1α. The level of nuclear HIF-1α was
cross-checked using immunoblotting (Fig. 6D) and immunofluorescence (Fig.
6E). Collectively, diacetoxyscirpenol seem to attenuate HIF-1 signaling in two
different ways.
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Diacetoxyscirpenol inhibits anchorageindependent cancer growth and
angiogenesis
Anchorage-independent cell growth is a representative property of cancer cells
with tumorigenic potential, and it has been reported to occur depending on
HIF-1α [Lee et al., 2013; Mills et al., 2009]. Therefore, I examined if
diacetoxyscirpenol can negate the tumorigenic potential of A549 cells using a
colony formation assay. At a glance, colonies of A549 were shown at a lesser
density in the presence of diacetoxyscirpenol (Fig. 7A). Both the number and
size of colonies were significantly reduced by diacetoxyscirpenol in a
dose-dependent manner (Fig. 7B). I next investigated if diacetoxyscirpenol
attenuates the angiogenic potential of cancer cells because HIF-1α plays a key
role in tumor angiogenesis [Pugh et al., 2003; Chang et al., 2006].
Diacetoxyscirpenol substantially inhibited VEGF secretion from A549 cells in
either normoxic or hypoxic conditions (Fig. 8A). As expected, diacetoxyscirpenol
attenuated the hypoxic induction of VEGF mRNA (Fig. 8B). To check the
angiogenic potential of A549 cells, tube formation of HUVECs was analyzed in
the presence of A549-driven conditioned media. Endothelial tube formation was
augmented by the conditioned media from A549 cells exposed to hypoxia.
However, in the conditioned media from A549 cells treated with
diacetoxyscirpenol, the tube formation was significantly reduced (Fig. 8C). To
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test the possibility that diacetoxyscirpenol per se inhibits the endothelial tube
formation, the compound was separately administered into the endothelial culture
plates containing conditioned media from hypoxic A549 cells. Given that the tube
formation was attenuated by diacetoxyscirpenol (Fig. 8D), diacetoxyscirpenol is
also likely to have a direct effect against vascular formation. These results
suggest that diacetoxyscirpenol inhibits tumorigenic and angiogenic potentials of
cancer cells under hypoxia.
Diacetoxyscirpenol inhibits the growth of lung carcinoma grafts in mice
To in vivo examine the anticancer activity of diacetoxyscirpenol, this agent was
administered into mice bearing Lewis lung carcinoma. When tumor volume
reached about 100 mm3, mice were intraperitoneally injected with DMSO
(vehicle) or diacetoxyscirpenol. No substantial changes in gross appearance and
body weight suggest that diacetoxyscirpenol at the used dose is not highly toxic
(Fig. 9A). Diacetoxyscirpenol retarded tumor growth (Fig. 9A), and excised
tumors were noticeably smaller in diacetoxyscirpenol-treated mice than in
vehicle-treated mice (Fig. 9B). The HIF-1α suppression by diacetoxyscirpenol
was confirmed by immunoblotting HIF-1α in tumor homogenates (Fig. 9C).
HIF-1α and Ki-67 (a marker for cell proliferation) were less expressed, and
22
vessels were poorly developed in tumor specimens from
diacetoxyscirpenol-treated mice (Fig. 9D and 9E). These results suggest that
diacetoxyscirpenol attenuates cancer cell proliferation by impairing tumor
adaptation to hypoxic microenvironment. However, given that the numbers of
TUNEL-stained apoptotic cells were not different between two groups, this
agent may not kill cancer cells directly.
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Figure 1. The 1st round screening of anti-HIF compounds in BHS-A503.
(A) Scheme for making Hep3B stable cell lines harboring the EPO
enhancer/luciferase reporter. (B) Scheme for searching for compounds having
anti-HIF activity. (C) Effects of BHS-A503 fractions against HIF-driven
transcription. EPO-Hep3B cells were treated with one of 40 fractions (100
ng/mL) form BHS-A503 for 4 hours, and then incubated at 1 % oxygen for 16
hours. Luciferase activities in cell lysates were measured using a luminometer.
(D) Effects of BHS-A503 fractions on cell viability. Hep3B cells were treated
with 100 ng/mL of each fraction for 24 hours, and cell viabilities were evaluated
by MTT assay. (E) Effects of BHS-A503 fractions on HIF-1α expression.
Hep3B cells were treated with 100 ng/mL of each fraction under hypoxia for 12
hours. HIF-1α and β-tubulin levels were analyzed by immunoblotting. All
results were obtained from 4 independent experiments and each bar represents






Figure 2. The 2nd round screening of anti-HIF compounds in BHS-A503
#26 fractions.
(A) Effects of #26 fractions against HIF-driven transcription. The EPO
enhancer/luciferase-harboring Hep3B cells were treated with one of 13 fractions
(10 ng/mL) from BHS-A503 # 26 for 4 hours, and then incubated under hypoxia
for 16 hours. Luciferase activities in cell lysates were measured using a
luminometer. (B) Effects of BHS-A503 # 26 fractions on cell viability. Hep3B
cells were treated with 10 ng/mL of each fraction for 24 hours, and cell
viabilities were evaluated by MTT assay. (C) Effects of BHS-A503 #26
fractions on HIF-1α expression. Hep3B cells were treated with 10 ng/mL of each
fraction under hypoxia for 12 hours. HIF-1α and β-tubulin levels were analyzed
by immunoblotting. All results were obtained from 4 independent experiments




Figure 3. Anti-HIF activity of compound #26-7.
(A and B) A549, HCT116, or MKN45 cells were pre-treated with # 26-7 for 4
hours, and further incubated under hypoxia for 8 hours. Protein levels were
analyzed by immunoblotting (top). Each bar represents the mean and standard
deviation (n = 3), and *and # denote P < 0.05 versus the hypoxic control
(bottom). (C) A549 cells, which had been co-transfected with the EPO
enhancer-luciferase and the CMV promoter-galactosidase plasmids (1 mg of
each), were treated with # 26-7 for 4 hours, and then incubated under hypoxia
for 16 hours. Luciferase activities were normalized to galactosidase activities,
which were presented as relative values to the normoxic control level. Each bar
represents the mean + standard deviation (n = 4) and *denotes P < 0.05 versus
the hypoxic control (the 2nd bar). (D) Quantitative RT-PCR was performed to
check the expression of HIF-targeted genes in A549 cells which were treated
with #26-7 under normoxia (N) or hypoxia (H) for 16 hours. Each assay was
done in triplicate and the result was divided by β-actin level in the
corresponding sample. Each bar represents the mean and standard deviation (n =






Figure 4. Identification of BHS-A503 #26-7.
(A) Compound # 26-7 was identified as diacetoxyscirpenol (DAS) in [α]D,
LR-EI-MS, and NMR (1H, 13C, DEPT) analyses. (B) Comparison of toxicities of
DAS among cancer cell and normal cells. A549, CCD-18Lu, and HEK293 were
treated with the indicated doses of DAS for 24 hours. Cell viability was
evaluated by MTT assay, and each bar represents the mean + standard
deviation from 3 independent experiments. (C) A549 cells were treated with 1.25
–10 ng/mL of DAS, which was purchased from a company, for 4 hours and
subjected to 8 hour-hypoxia. Protein levels were analyzed by immunoblotting.
Each bar represents the mean and standard deviation (n = 3), and * and # denote
P < 0.05 versus the hypoxic control. (D) A549 cells, which had been
co-transfected with EPO enhancer-luciferase and galactosidase plasmids (1 mg of
each), were treated with DAS for 4 hours and incubated under hypoxia for 16
hours. Luciferase activities were normalized to galactosidase activities and are
presented as relative values to the normoxic control. Each bar represents the
mean and standard deviation (n = 4) and *denotes p < 0.05 versus the hypoxic
control. (E) A549 cells harboring the EPO-Luc plasmid were treated with DAS
or 17AAG at the indicated concentrations for 4 hours, and incubated under
hypoxia for 16 hours. Luciferase activities in drug-treated groups were divided
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by those in drug-free group. Each bar represents the mean and standard
deviation (n = 4), and the half maximal inhibitory concentration (IC 50) was






Figure 5. Diacetoxyscirpenol downregulates HIF-1α in the translational
level.
(A) Effect of DAS on oxygen-dependent degradation of HIF-1α. A549 cells were
incubated with DMSO or DAS under hypoxia for 12 hours. Following
re-oxygenation for the indicated periods (0 to 10 minutes), cells were lysed and
HIF-1α levels were analyzed by immunoblotting. (B) After treated with 500 μM
DMOG for 8 hours, A549 cells were pre-incubated with DMSO or DAS (10
ng/mL) for 1 hour, and then treated with 10 mg/mL of CHX for the indicated
times. HIF-1α levels were determined by immunoblotting. (C) Effect of DAS on
de novo synthesis of HIF-1α protein. After treated with DMSO or DAS 4 hours,
A549 cells were additionally treated with 10 μM MG132 to induce the
accumulation of newly synthesized HIF-1α. HIF-1α levels were determined at
the indicated times (0 to 8 hours) by immunoblotting (top). Each bar represents
the mean and standard deviation (n = 3), and *denotes P < 0.05 versus the
DMSO control at the corresponding time (bottom). (D) Effect of DAS on the
transcription of the HIF-1α gene. Quantitative RT-PCR was performed to check
the HIF-1α mRNA level in A549 cells which were treated with DAS for 16
hours. Each assay was done in triplicate and the result was divided by β-actin
level in the corresponding sample. Each bar represents the mean and standard
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deviation (n = 4). (E) Effect of DAS on the 5‘UTR-driven translation of HIF-1α.
Cap-dependent and IRES-dependent translational rates of HIF-1α were analyzed
using TK promoter-5‘ UTR-luciferase and CMV promoter-GFP-5‘UTR-luciferase
reporters, respectively. The TK promoter-luciferase vector was used as a
background control. A549 cells, which had been co-transfected with one of these
reporters and galactosidase plasmids, were subjected to 16 hour-hypoxia in the
absence or presence of DAS. Luciferase activities were normalized to
galactosidase activities and are presented as relative values to the normoxic
control. Each bar represents the mean and standard deviation (n = 4) and






Figure 6. Diacetoxyscirpenol blocks the formation of the HIF-1 complex.
(A) After treated with DAS for 4 hours, A549 cells were incubated with 0.5 mM
DMOG to inhibit the hydroxylation of HIF-1α, and subjected to immunoblotting.
(B) VHL-null RCC4 cells were treated with DAS for 12 hours, and subjected to
immunoblotting. (C) A549 cells were pretreated with DAS (5 ng/mL) for 4
hours, and further incubated under hypoxia for 8 hours. HIF-1α or ARNT were
precipitated with the indicated antibodies, and then, the precipitates was
subjected to immunoblotting. The specificity of immunoprecipitation was verified
using non-immunized serum (IgG). (D) The lysates of A549 cells, which had
been treated as indicated, were separated into the cytosolic and nuclear fractions,
which were subjected to immunoblotting. Lamin B and β-tubulin were analyzed
to verify the specificity of each fraction. (E) A549 cells were treated DMSO or
DAS (5 ng/mL) under normoxic or hypoxic conditions for 16 hours. The cells
were co-stained with anti-HIF-1α antibody (green) and DAPI (blue). The









Figure 7. Effects of diacetoxyscirpenol on the colonial growth of A549
cancer cells.
(A) After treated with DAS twice a week for 3 weeks, A549 cells in the top
agar were stained with 0.05 % crystal violet. (B) Colony size was measured
using Image J and colonies whose sizes were over 0.2 mm2 were counted. Each
bar represents the mean + standard deviation (n = 4) and *denotes P < 0.05




Figure 8. Anti-angiogenic effect of diacetoxyscirpenol.
(A) The conditioned media were collected from A549 cells which had been
incubated with DAS under normoxic or hypoxic conditions. The concentrations
(means + standard deviation, n = 4) of VEGF in the conditioned media were
measured using an ELISA kit. * and # denote P < 0.05 versus the normoxic
control and the hypoxic control, respectively. (B) After A549 cells were treated
with DAS for 24 hours under hypoxia, the VEGF mRNA levels were analyzed
by quantitative RT-PCR. Each assay was done in triplicate and the VEGF level
was divided by β-actin level in the corresponding sample. Each bar presents the
mean + standard deviation (n = 4) of relative values and * denotes P < 0.05
versus the hypoxic control. (C) HUVECs were cultured on Matrigel ™-coated
plates for 16 hours in the conditioned media from A549 cells which had been
treated with DAS for 24 hours under normoxic or hypoxic conditions. The
reorganization of HUVECs was pictured under an inverted microscope.
Quantitative analyses of tube lengths (mm) and tube area (% of total area)
were performed using Image J. (D) After A549 cells were incubated for 24 hours
under normoxic or hypoxic conditions, conditioned media were collected and
applied to HUVECs in Matrigel ™-coated plates. HUVECs were further
incubated with DMSO or DAS for 16 hours. HUVECs were photographed and
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endothelial tubes were quantified using Image J. Each bar presents the mean +








Figure 9. Anticancer effect of diacetoxyscirpenol.
(A) Tumor growth curves. LCC1 cells were grafted on the flanks of mice, and
the tumor-bearing mice were injected daily with vehicle (n = 6) or 1 mg/kg of
DAS (n = 6) for 2 weeks. Each circle represents the mean and standard deviation
of body weight (top) or tumor volume (bottom). *denotes P < 0.05 vs. the
vehicle group. (B) Gross appearance of tumorbearing mice or excised tumors.
(C) In tumor homogenates, HIF-1α protein was immunoblotted (left), its level
was analyzed using ImageJ (right). Each bar represents the mean + standard
deviation (n = 5) and * denotes P < 0.05 versus the vehicle control. (D)
Immunohistochemical analyses. Excised tumors were fixed, paraffin-embedded,
and cut into 4 mm sections. The specimens were stained with hematoxylin and
eosin (H&E), or immunostained with anti-HIF-1α, anti-CD31 and anti-Ki-67
antibodies. TUNEL staining was performed to detect cancer cells undergoing
apoptosis. (E) Four fields (x400 magnification) per section and four sections of
each tumor were reviewed for histologic assessments. HIF-1α, CD31, Ki-67,
TUNEL-positive cells were counted, and the areas of CD31-positive vessel were
measured using the Image J. Each bar represents the mean + standard deviation






Figure 10. Schematic summary of the role of diacetoxyscirpenol on HIF-1.
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DISCUSSION
To find a new anticancer small molecule to target HIF-1, I performed the
high-throughput screening using a luciferase reporter system reflecting
HIF-driven transcription, and finally selected a marine bacterial extract based on
high potency on HIF inhibition and less cytotoxicity. Through two fractionation
processes of the extract, diacetoxyscirpenol was purified and identified as an
active ingredient having anti-HIF activity. Mechanistically, diacetoxyscirpenol
repressed HIF-1 by inhibiting either HIF-1α translation or its dimerization with
ARNT (Fig. 10). Furthermore, diacetoxyscirpenol blunted HIF-mediated induction
of hypoxic genes, and by doing so attenuated anchorage-independent colony
formation, endothelial tube formation, and tumor growth in mice. Therefore, I
propose that diacetoxyscirpenol be a potential anticancer agent targeting HIF-1.
To search for compounds inhibiting the HIF-1 signaling pathway, I performed
two different methods to evaluate this pathway, namely, the HRE-luciferase
reporter and Western blotting for HIF-1α. However, as shown in Fig. 1C and
1E and in Fig. 2A and 2C, the results from the two analyses were somewhat
missmatched with each other.
Actually, the functionality of HIF-1 is determined by diverse factors other than
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the amount of HIF-1α protein. For instance, HIF-1α is modified (i.e.,
hydroxylated, phosphorylated, sumoylated, and neddyated), and interacts with
many proteins, thereby modulating the HIF-1 activity [Brahimi et al., 2005;
Dengler et al., 2014]. The discrepancies between the results from two analyses
may be attributed to the post-translation regulations of HIF-1α. Therefore, I
chose the compounds that inhibited HIF-1 at both the analyses.
Diacetoxyscirpenol contains the 12, 13-epoxytrichothecene group of sesquiterpenes
as the core structure. It has been known as one of harmful metabolites produced
from plant parasitic fungi belonging to Fusarium species [Dawkins et al., 1996].
Accidently, people or livestock have been subjected to food poisoning by
diacetoxyscirpenol which contaminated agricultural crops, such as grains,
potatoes, peas, soybeans [Egmond et al., 2007]. However, diacetoxyscirpenol has
been rarely reported to contaminate sea plants. Surprisingly, diacetoxyscirpenol
was found to be also contained in a marine bacterium parasitizing red alga,
suggesting that diacetoxyscirpenol probably cause food poisoning derived by sea
foods. For keeping sea foods safe, it may be recommended to check the
contamination of diacetoxyscirpenol.
Diacetoxyscirpenol and its analogues were developed as anti-cancer agents
because it inhibited cell cycle progression and cell survival [Jun et al., 2007].
Diacetoxyscirpenol was also reported to potentiate the anti-cancer effect of
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cisplatin [Hromas et al., 1986]. However, the clinical trial of diacetoxyscirpenol
for cancer treatment was ceased at the phase II because it induced intolerable
side effects, such as nausea, vomiting, fever, hypertension, and confusion
[Bukowski et al., 1982; Yap et al., 1979]. Nonetheless, I argue that
diacetoxyscirpenol can be repositioned as an anti-HIF agent. Compared to the
concentrations (> 100 nM) of diacetoxyscirpenol used to kill cancer cells directly
[Dosik et al., 1978], a lower concentration (< 5 nM) of diacetoxyscirpenol was
found in our experiments to inhibit HIF-1. Indeed, cell viability was not
substantially decreased by diacetoxyscirpenol at this concentration. If its dose is
readjusted to a HIF-inhibiting level, diacetoxyscirpenol is expected to come out
as a potential drug that specifically blocks hypoxia-triggered, malignant cancer
behaviors, such as angiogenesis, metastasis, and drug resistance.
Diacetoxyscirpenol was shown to block the hypoxia induced production of
VEGF, which is a target gene of HIF-1. VEGF does not only drives
angiogenesis but also acts as a cell survival factor, which is why VEGF
inhibitors have been widely used as anti-cancer drugs. For example,
bevacizumab interferes with VEGF binding to the VEGF receptors by
sequestering VEGF, and inhibitors of VEGF receptor tyrosine kinase block the
signaling pathway of the VEGF receptors [Ferrara et al., 2004; Press et al.,
2007]. Diacetoxyscirpenol inhibited the VEGF secretion from cancer cells under
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hypoxia, thereby inhibiting the endothelial tube formation. Although it does not
directly target endothelial cells, diacetoxyscirpenol may indirectly inhibit
tumor-driven angiogenesis at least under hypoxic microenvironment. Some
anti-angiogenic agents, mostly in combination with conventional therapeutics,
have been shown to have anticancer activity in preclinical and clinical studies
[Ma et al., 2008]. However, the pros and cons of anti-angiogenic agents have
been debated so far. In some preclinical studies, co-administration of
anti-angiogenic agents was shown to aggravate tumor hypoxia and also to
impair the delivery of cancer cell-targeting drugs, leading to acquired resistance
to chemotherapy [Huang et al., 2015]. By contrast, beneficial actions of
anti-angiogenic agents in combination therapies have been also suggested. These
agents may improve oxygen and drug delivery within tumors through
normalization of irregular tumor vessels [Carmeliet et al., 2011]. Since the
anti-angiogenic action of diacetoxyscirpenol may contribute to its anticancer
effect, this conflicting point should be considered in developing
diacetoxyscirpenol as an adjuvant cancer drug.
In conclusion, I found that diacetoxyscirpenol deregulates tumor adaptation to
hypoxia by deregulating HIF-1α. To our best knowledge, diacetoxyscirpenol is
for the first time identified to inhibit HIF-1. More importantly, it is possible that
diacetoxyscirpenol is used as a HIF-1 inhibitor at a lesser dose than its
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cytotoxic dose. If a low dose of diacetoxyscirpenol is limitedly used for the
purpose of preventing HIF-mediated tumor progression or drug resistance, it
may be worthwhile reevaluating this agent as an adjuvant cancer drug.
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국 문 초 록
저산소 유도인자 (HIF)는 세포의 저산소 적응과정에서 핵심적인 역할을 한다. 특히
고형암은 저산소 상황에서 암세포의 생존과 혈관형성에 필요한 HIF를 다량으로 발
현하므로 HIF를 표적으로 하는 치료제를 개발하는 것이 중요하다. 본 연구에서는
HIF를 효과적으로 억제할 수 있는 새로운 약물을 찾기 위한 실험을 진행하였다. 총
7,280개의 화합물 후보군은 EPO 프로모터와 Luciferase 퓨전 벡터를 리포터로 넣어
준 간암세포주인 Hep3B를 이용하여 HIF의 활성도를 측정하였으며 그 중에서 최종
후보군을 선정하였다. 구조분석을 통해 최종후보군으로 선택된 단일물질이
diacetoxyscirpenol임을 확인하였다. Diacetoxyscirpenol은 여러 암세포에서 HIF의
단백질 발현을 억제할 뿐만 아니라, HIF의 활성 및 HIF에 의해 유도되는 하위유전
자들의 발현을 억제하였다. 또한 혈관형성과 암세포의 성장을 억제하며 동물실험에
서도 암의 성장을 효과적으로 억제하였다. Diacetoxyscirpenol은 HIF의 합성과정을
억제하며 HIF와 ARNT의 결합을 억제함으로서 저산소 관련인자의 발현을 억제함
을 확인하였다. 이러한 결과를 통해 본 연구는 Diacetoxyscirpenol가 저산소 조건에
노출되어 있는 고형암을 치료할 수 있는 새로운 약물로서 사용될 수 있을 것으로
사료된다.
주요어 : 암, 저산소, HIF-1, Diacetoxyscirpenol, Drug screening.
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